5 Top Biotech and Drug Stocks Spiking Higher Before Earnings

Merck & Co., Inc. (NYSE:MRK) will unveil its latest earnings on Friday, October 28, 2011. The average estimate of analysts is for net income of 91 cents per share, a rise of 7.1% from the company’s actual earnings for the same quarter a year ago. The average estimate is the same as three months ago. Between one and three months ago, the average estimate moved down. It has risen from 90 cents during the last month. Analysts are projecting profit to rise by 9.1% versus last year to $3.73.

The company met estimates last quarter after beating the forecasts in the prior two. In the second quarter, the company reported profit of 95 cents per share versus a mean estimate of net income of 95 cents per share. In the first quarter, the company beat estimates by 8 cents. Revenue analysts are projecting a rise of 4.4% in revenue from the year-earlier quarter to $11.61 billion.

Competitors to Watch: Johnson & Johnson (NYSE:JNJ), Pfizer Inc. (NYSE:PFE), Bristol Myers Squibb Co. (NYSE:BMY), GlaxoSmithKline plc (NYSE:GSK), Sanofi-Aventis SA (NYSE:SNY), Roche Holding Ltd. (RHHBY), Eli Lilly & Co. (NYSE:LLY), Abbott Laboratories (NYSE:ABT), Teva Pharmaceutical Industries Ltd (NASDAQ:TEVA), and Novartis AG (NYSE:NVS).

 Biogen Idec, Inc. (NASDAQ:BIIB) will unveil its latest earnings on Friday, October 28, 2011. The average estimate of analysts is for net income of $1.51 per share, a rise of 13.5% from the company’s actual earnings for the same quarter a year ago. During the past three months, the average estimate has moved up from $1.48. Between one and three months ago, the average estimate moved up. It has been unchanged at $1.51 during the last month. Analysts are projecting profit to rise by 16.3% versus last year to $5.85.

The company missed estimates last quarter after beating forecasts in the prior two. In the second quarter, the company reported profit of $1.35 per share versus a mean estimate of net income of $1.39 per share. In the first quarter, the company beat estimates by 3 cents. Revenue on average, analysts predict $1.27 billion in revenue this quarter, a rise of 7.6% from the year ago quarter. Analysts are forecasting total revenue of $4.96 billion for the year, a rise of 5.1% from last year’s revenue of $4.72 billion.

Competitors to Watch: Elan Corp., plc (NYSE:ELN), Amgen, Inc. (NASDAQ:AMGN), Roche Holding Ltd. (RHHBY), Teva Pharmaceutical Industries Ltd (NASDAQ:TEVA), Abbott Laboratories (NYSE:ABT), Merck & Co., Inc. (NYSE:MRK), Genzyme Corporation (NASDAQ:GENZ), Pfizer Inc. (NYSE:PFE), GlaxoSmithKline plc (NYSE:GSK), and Bristol Myers Squibb Co. (NYSE:BMY).

Celgene Corporation (NASDAQ:CELG) will unveil its latest earnings on Thursday, October 27, 2011.  The average estimate of analysts is for profit of 86 cents per share, a rise of 32.3% from the company’s actual earnings for the same quarter a year ago. During the past three months, the average estimate has moved up from 78 cents. Between one and three months ago, the average estimate moved up. It has risen from 85 cents during the last month. Analysts are projecting profit to rise by 33.2% versus last year to $3.25.

Last quarter, the company topped expectations by one cent, coming in at net income of 78 cents per share versus a mean estimate of profit of 77 cents per share. This followed two straight quarters of missing estimates. Revenue on average, analysts predict $1.2 billion in revenue this quarter, a rise of 32.1% from the year ago quarter. Analysts are forecasting total revenue of $4.71 billion for the year, a rise of 30.1% from last year’s revenue of $3.62 billion.

Competitors to Watch: Novartis AG (NYSE:NVS), SuperGen, Inc. (NASDAQ:SUPG), Pfizer Inc. (NYSE:PFE), GlaxoSmithKline plc (NYSE:GSK), Bristol Myers Squibb Co. (NYSE:BMY), Genzyme Corporation (NASDAQ:GENZ), Cell Therapeutics, Inc. (NASDAQ:CTIC), Merck & Co., Inc. (NYSE:MRK), Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI), and Sanofi-Aventis SA (NYSE:SNY).

 Bristol-Myers Squibb Co. (NYSE:BMY) will unveil its latest earnings on Thursday, October 27, 2011. The average estimate of analysts is for profit of 58 cents per share, a decline of 1.7% from the company’s actual earnings for the same quarter a year ago. During the past three months, the average estimate has moved up from 55 cents. Between one and three months ago, the average estimate moved up. It has risen from 57 cents during the last month. For the year, analysts are projecting net income of $2.28 per share, a rise of 5.6% from last year.

The company is looking to make a streak of three quarters of beating estimates. Last quarter, it beat expectations by reporting profit of 56 cents per share, and the previous quarter, it had net income of 58 cents. Revenue analysts are projecting a rise of 10.4% in revenue from the year-earlier quarter to $5.3 billion.

Competitors to Watch: Pfizer Inc. (NYSE:PFE), Merck & Co., Inc. (NYSE:MRK), Eli Lilly & Co. (NYSE:LLY), Sanofi-Aventis SA (NYSE:SNY), Abbott Laboratories (NYSE:ABT), Novartis AG (NYSE:NVS), Johnson & Johnson (NYSE:JNJ), GlaxoSmithKline plc (NYSE:GSK), and AstraZeneca plc (NYSE:AZN).

Gilead Sciences, Inc. (NASDAQ:GILD) will unveil its latest earnings on Thursday, October 27, 2011.  The average estimate of analysts is for net income of 96 cents per share, a rise of 12.9% from the company’s actual earnings for the same quarter a year ago. During the past three months, the average estimate has moved down from 98 cents. Between one and three months ago, the average estimate moved down. It has been unchanged at 96 cents during the last month. For the year, analysts are projecting profit of $3.74 per share, a rise of 6.6% from last year.

Last quarter, the company missed estimates by one cent, coming in at net income of 95 cents per share against an estimate of profit of. In the first quarter, the company also missed expectations. Revenue analysts are projecting a rise of 8.8% in revenue from the year-earlier quarter to $2.11 billion.

Competitors to Watch: GlaxoSmithKline plc (NYSE:GSK), Pfizer Inc. (NYSE:PFE), Merck & Co., Inc. (NYSE:MRK), Johnson & Johnson (NYSE:JNJ), Bristol Myers Squibb Co. (NYSE:BMY), Idenix Pharmaceuticals, Inc. (NASDAQ:IDIX), Trimeris, Inc. (NASDAQ:TRMS), BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX), and Hemispherx BioPharma, Inc (AMEX:HEB).